> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Why the FDA Overrode Its Advisers on Camizestrant
- URL: https://bioweek.com/why-the-fda-overrode-its-advisers-on-camizestrant/
- Published: 2026-09-07T05:07:08.000Z
- Updated: 2026-09-07T05:07:08.000Z
- Description: The FDA granted accelerated approval to AstraZeneca’s camizestrant based on ctDNA resistance signals before radiographic progression, overruling a 6-3 advisory committee vote and betting on a new oncology paradigm.
- Author: BioWeek
- Tags: Policy, Pipeline

On September 4, 2026, the FDA [granted](\"https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment\") accelerated approval to AstraZeneca's camizestrant (Etcamah) plus a CDK4/6 inhibitor for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer once an ESR1 mutation is found during aromatase inhibitor and CDK4/6 inhibitor therapy, using an FDA-authorized test. Palbociclib, ribociclib, or abemaciclib can be the partner. The [decision](\"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative\") is the first U.S. cancer approval steered by a resistance mutation in circulating tumor DNA before scans show that tumors have grown.

Angelo de Claro, M.D., director of the FDA's Oncology Center of Excellence, said the agency had never before [approved](\"https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-breast-cancer-treatment\") a cancer therapy on a ctDNA resistance signal ahead of radiographic progression, and that more evidence is still needed to confirm clinical benefit. Guardant Health's Guardant360 CDx was cleared in parallel as the companion diagnostic. The file moved under Project Orbis with regulators in Australia, Canada, Brazil, Singapore, and Switzerland.

### A 6-3 vote the agency declined to follow

The fight started earlier. On April 30, 2026, the Oncologic Drugs Advisory Committee [voted](\"https://www.cancernetwork.com/view/fda-odac-no-camizestrant-for-hr-her2-esr1-advanced-breast-cancer\") 6 to 3 against the application. Skeptics, including Dr. Stanley Lipkowitz of the National Cancer Institute, argued that acting on ctDNA changes the definition of progression without an overall survival advantage. Earlier switching can look like a delay simply because the clock starts sooner, a lead-time problem, and should not reset first-line practice on a surrogate.

Supporters, including Dr. Toni Choueiri of Dana-Farber, cited a large delay in radiographic progression and a benefit-risk balance they judged acceptable for patients already heading toward endocrine failure. AstraZeneca [defended](\"https://www.astrazeneca.com/media-centre/press-releases/2026/fda-odac-vote-on-camizestrant-breast-cancer.html\") the interception design after the vote. Four months later, FDA overrode the panel, issued accelerated approval, and required confirmatory post-marketing studies under Project Confirm. Clinics can now switch on a blood test. Survival remains unproven.

### What SERENA-6 actually measured

The [trial](\"https://www.nejm.org/doi/full/10.1056/NEJMoa2502929\"), SERENA-6 (NCT04964934), enrolled 315 patients with ER-positive, HER2-negative advanced breast cancer on first-line anastrozole or letrozole plus a CDK4/6 inhibitor for at least six months without radiographic progression. About 75 percent were on palbociclib. Serial ctDNA checks ran every two to three months. When an ESR1 mutation appeared, patients were randomized 1:1, 157 to camizestrant and 158 to continued aromatase inhibitor.

Median progression-free survival was 16.0 months (95% CI: 12.7-18.2) with camizestrant versus 9.2 months (95% CI: 7.2-9.5) in the control arm. The hazard ratio was 0.44 (95% CI: 0.31-0.60; p < 0.00001), a 56 percent reduction in the risk of progression or death. At 24 months, 29.7 percent of patients on camizestrant still had disease control, compared with 5.4 percent on continued aromatase inhibitor. Time to second progression (PFS2) was 25.7 months versus 19.1 months (hazard ratio 0.63; 95% CI: 0.46-0.86; p = 0.00373). Overall survival was immature at approval, with an interim hazard ratio of 0.87 (95% CI: 0.57-1.30). The PFS result is clear. The OS interval crosses 1.0.

### Why ESR1 shows up on a blood test first

Aromatase inhibitors starve estrogen-dependent tumors of ligand. Under that pressure, clones with ESR1 mutations in the ligand-binding domain drive receptor transcription without estrogen. Those mutations are uncommon at first metastatic diagnosis, under 5 percent, then appear in nearly 40 percent of patients after aromatase inhibitor therapy. Camizestrant is an oral selective estrogen receptor degrader that binds the receptor and marks it for destruction, including mutated forms that no longer need ligand.

Elacestrant (Orserdu), Menarini's oral SERD, is approved only after radiographic progression. Camizestrant is labeled to intercept in the first-line setting while imaging is still stable. The biology of ESR1 emergence is not in dispute. Whether a liquid-biopsy trigger should replace the scan as the moment to change therapy is the policy fight FDA just decided, pending confirmatory data.

### A boxed warning and a denser toxicity profile

The label is not a free switch. Prescribing information carries a Boxed Warning for arrhythmia from QTc prolongation when camizestrant is given with other QTc-prolonging drugs, plus warnings for bradycardia and embryo-fetal toxicity. The recommended dose is 75 mg orally once daily.

Grade 3 or higher adverse events occurred in 60 percent of patients on camizestrant versus 46 percent on aromatase inhibitor, driven mainly by neutropenia (45 percent versus 34 percent) and leukopenia (10 percent versus 3 percent). Anemia was 5 percent in both arms. Transient photopsia was observed. For patients already on CDK4/6 inhibitors, the neutropenia increment is a clinic problem.

### The testing burden the label assumes

SERENA-6's efficacy curve exists only because investigators looked for ESR1 every two to three months in patients still responding on scans. Widespread use therefore means routine serial liquid biopsy in asymptomatic first-line patients, a companion assay, and payer coverage for tests that do not yet correspond to a growing mass on imaging. Guardant360 CDx is now the authorized gate. Capacity, reimbursement, and how quickly community practices can run that cadence will decide how many patients actually see the 16-month PFS the [study](\"https://www.nejm.org/doi/full/10.1056/NEJMoa2502929\") reported.

Accelerated approval lets FDA move before OS matures. Project Confirm is the backstop. Until those data arrive, camizestrant is a new endocrine option and a live test of whether ctDNA can outrun the scan.